Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a strong-buy rating in a research note published on Tuesday morning.

COLL has been the subject of a number of other reports. Jefferies Financial Group reissued a hold rating and set a $37.00 price target (up from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Truist Financial boosted their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a buy rating in a research report on Monday, February 26th. Piper Sandler reaffirmed an overweight rating and set a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Finally, Needham & Company LLC reissued a buy rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $39.00.

Collegium Pharmaceutical Stock Up 3.5 %

COLL stock opened at $35.94 on Tuesday. Collegium Pharmaceutical has a 52 week low of $20.83 and a 52 week high of $40.95. The firm has a 50 day moving average of $36.97 and a 200 day moving average of $31.11. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48. The stock has a market capitalization of $1.18 billion, a PE ratio of 30.46 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. The company had revenue of $149.75 million during the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. Sell-side analysts forecast that Collegium Pharmaceutical will post 5.63 earnings per share for the current year.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SummerHaven Investment Management LLC boosted its stake in shares of Collegium Pharmaceutical by 1.1% during the 4th quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after acquiring an additional 368 shares in the last quarter. Illinois Municipal Retirement Fund boosted its position in Collegium Pharmaceutical by 2.1% during the fourth quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company’s stock worth $612,000 after purchasing an additional 411 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Collegium Pharmaceutical by 0.8% in the third quarter. Los Angeles Capital Management LLC now owns 76,876 shares of the specialty pharmaceutical company’s stock valued at $1,718,000 after purchasing an additional 585 shares during the period. Swiss National Bank increased its position in shares of Collegium Pharmaceutical by 1.1% in the third quarter. Swiss National Bank now owns 76,100 shares of the specialty pharmaceutical company’s stock valued at $1,701,000 after buying an additional 800 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Collegium Pharmaceutical by 5.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,713 shares of the specialty pharmaceutical company’s stock worth $514,000 after buying an additional 868 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.